NASDAQ:BASIBioanalytical Systems Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bioanalytical Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.36 +0.17 (+3.28 %) (As of 08/10/2020 11:21 AM ET) Add Compare Share Today's Range$5.36Now: $5.36▼$5.3650-Day Range$4.70MA: $5.14▼$5.4552-Week Range$2.00Now: $5.36▼$6.50Volume40 shsAverage Volume36,990 shsMarket Capitalization$58.21 millionP/E RatioN/ADividend YieldN/ABeta1.49 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment also provides in vivo sampling services for the continuous monitoring of chemical changes in life; non-clinical and pathology services; analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Bioanalytical Systems. Previous Next 2.3 Community Rank Outperform VotesBioanalytical Systems has received 124 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBioanalytical Systems has received 151 “underperform” votes. (Add your “underperform” vote.)Community SentimentBioanalytical Systems has received 54.91% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Bioanalytical Systems and other stocks. Vote “Outperform” if you believe BASI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BASI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBioanalytical Systems does not currently pay a dividend.Dividend GrowthBioanalytical Systems does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bioanalytical Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $81,809.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 11.46% of the stock of Bioanalytical Systems is held by insiders.Percentage Held by InstitutionsOnly 11.16% of the stock of Bioanalytical Systems is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioanalytical Systems is -28.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioanalytical Systems is -28.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioanalytical Systems has a P/B Ratio of 5.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.06 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BASI Previous Symbol CUSIPN/A CIK720154 Webwww.basinc.com Phone765-463-4527Debt Debt-to-Equity Ratio1.89 Current Ratio0.53 Quick Ratio0.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$43.62 million Price / Sales1.33 Cash Flow$0.22 per share Price / Cash Flow24.72 Book Value$1.02 per share Price / Book5.25Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-790,000.00 Net Margins-3.94% Return on Equity-12.39% Return on Assets-2.51%Miscellaneous Employees224 Outstanding Shares10,860,000Market Cap$58.21 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable $5.36 +0.17 (+3.28 %) (As of 08/10/2020 11:21 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BASI News and Ratings via Email Sign-up to receive the latest news and ratings for BASI and its competitors with MarketBeat's FREE daily newsletter. Bioanalytical Systems (NASDAQ:BASI) Frequently Asked Questions How has Bioanalytical Systems' stock been impacted by COVID-19 (Coronavirus)? Bioanalytical Systems' stock was trading at $4.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BASI shares have increased by 24.4% and is now trading at $5.36. View which stocks have been most impacted by Coronavirus. When is Bioanalytical Systems' next earnings date? Bioanalytical Systems is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Bioanalytical Systems. How were Bioanalytical Systems' earnings last quarter? Bioanalytical Systems, Inc. (NASDAQ:BASI) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company earned $16.01 million during the quarter. Bioanalytical Systems had a negative return on equity of 12.39% and a negative net margin of 3.94%. View Bioanalytical Systems' earnings history. Has Bioanalytical Systems been receiving favorable news coverage? Media coverage about BASI stock has been trending very positive on Monday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bioanalytical Systems earned a daily sentiment score of 3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Bioanalytical Systems. Who are some of Bioanalytical Systems' key competitors? Some companies that are related to Bioanalytical Systems include Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Auxly Cannabis Group (CBWTF), BIOQUAL (BIOQ), AIkido Pharma (AIKI), Cleveland BioLabs (CBLI), HedgePath Pharmaceuticals (HPPI), Tenax Therapeutics (TENX), Geovax Labs (GOVX), Vitality Biopharma (VBIO), US Stem Cell (USRM), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY) and Redpoint Bio (RPBC). View all competitors. What other stocks do shareholders of Bioanalytical Systems own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioanalytical Systems investors own include Athersys (ATHX), NovaBay Pharmaceuticals (NBY), Exxon Mobil (XOM), Enphase Energy (ENPH), Energy Recovery (ERII), GASTAR EXPL INC/SH (GST), Idera Pharmaceuticals (IDRA), Lattice Semiconductor (LSCC), Luna Innovations (LUNA) and Overstock.com (OSTK). Who are Bioanalytical Systems' key executives? Bioanalytical Systems' management team includes the following people: Mr. Philip A. Downing, Sr. VP of Preclinical Services (Age 49)Ms. Jill C. Blumhoff, CFO, VP of Fin. & Sec. (Age 43)Mr. Robert Leasure Jr., Pres, CEO & Director (Age 59)Dr. Peter T. Kissinger, Founder, Chairman Emeritus & Scientific Advisor (Age 74)Mr. D. Thomas Oakley, Chief Operating Officer What is Bioanalytical Systems' stock symbol? Bioanalytical Systems trades on the NASDAQ under the ticker symbol "BASI." How do I buy shares of Bioanalytical Systems? Shares of BASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Bioanalytical Systems' stock price today? One share of BASI stock can currently be purchased for approximately $5.36. How big of a company is Bioanalytical Systems? Bioanalytical Systems has a market capitalization of $58.21 million and generates $43.62 million in revenue each year. Bioanalytical Systems employs 224 workers across the globe. What is Bioanalytical Systems' official website? The official website for Bioanalytical Systems is www.basinc.com. How can I contact Bioanalytical Systems? Bioanalytical Systems' mailing address is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. The company can be reached via phone at 765-463-4527 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
